Trial Profile
A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2018
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin
- Indications Acute coronary syndromes
- Focus Adverse reactions
- Acronyms Brilinta DaYu; DAYU
- Sponsors AstraZeneca
- 13 Oct 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 02 Feb 2015 Planned End Date changed from 1 Oct 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
- 02 Feb 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.